Increasing Ten-Year Burden of Pediatric Type 1 Diabetes Mellitus in Southeastern Wisconsin: Relationship with Body Weight at Diagnosis

2007 ◽  
Vol 17 (9) ◽  
pp. 731-732
Author(s):  
J.M. Evertsen ◽  
R. Alemzadeh ◽  
X. Wang





2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Marcin Braun ◽  
Bartlomiej Tomasik ◽  
Ewa Wrona ◽  
Wojciech Fendler ◽  
Przemyslawa Jarosz-Chobot ◽  
...  

Introduction. It remains unclear howHbA1crecommendations influence metabolic control of paediatric patients with type 1 diabetes mellitus. To evaluate this we compared reportedHbA1cwith guideline thresholds.Materials and Methods. We searched systematically MEDLINE and EMBASE for studies reporting onHbA1cin children with T1DM and grouped them according to targetedHbA1cobtained from regional guidelines. We assessed the discrepancies in the metabolic control between these groups by comparing meanHbA1cextracted from each study and the differences between actual and targetedHbA1c.Results. We included 105 from 1365 searched studies. The median (IQR)HbA1cfor the study population was 8.30% (8.00%–8.70%) and was lower in “6.5%” than in “7.5%” as targetedHbA1clevel (8.20% (7.85%–8.57%) versus 8.40% (8.20%–8.80%);p=0.028). Median difference between actual and targetedHbA1cwas 1.20% (0.80%–1.70%) and was higher in “6.5%” than in “7.5%” (1.70% (1.30%–2.07%) versus 0.90% (0.70%–1.30%), resp.;p<0.001).Conclusions. Our study indicates that the 7.5% threshold results inHbA1clevels being closer to the therapeutic goal, but the actual values are still higher than those observed in the “6.5%” group. A meta-analysis of raw data from national registries or a prospective study comparing both approaches is warranted as the next step to examine this subject further.



Hypertension ◽  
2009 ◽  
Vol 54 (5) ◽  
pp. 987-994 ◽  
Author(s):  
Daniela Lucini ◽  
Gianvincenzo Zuccotti ◽  
Mara Malacarne ◽  
Andrea Scaramuzza ◽  
Sara Riboni ◽  
...  


Author(s):  
Sultan Ali Alshehri ◽  
Sultan Abdulwahab M. Asiri ◽  
Aalaa Mohammad Algarni ◽  
Manal Mohammed Alamari

Background: Type 1 diabetes mellitus is the main risk factor for cardiovascular complications. Therefore, intensified insulin therapy might be needed to achieve better glycemic control in some patients. However, insulin therapy might lead to increase body weight and induce hypoglycemia. Increase body weight is directly correlated to insulin resistance, the main factor for cardiovascular risk.  Objective: To assess the effectiveness of adding SGLT2 inhibitors to insulin therapy in type 1 diabetes mellitus.  Methods: We searched in the PubMed database looking for relevant articles on the topic. We used Mesh words search, including SGLT2 inhibitor, sotagliflozin, type 1 diabetes mellitus, insulin treatment.  Conclusion: Adding oral antidiabetic agents, such as SGLT2 or dual SGLT inhibitors to insulin regimen might be beneficial in improving insulin resistance. Thus, it achieved better insulin resistance by decrease daily insulin requirements and bodyweight control, leading to better cardiovascular outcomes among Type-1 diabetes patients.



2012 ◽  
Vol 105 (10) ◽  
pp. 513-517 ◽  
Author(s):  
Avnish Tripathi ◽  
Ali A. Rizvi ◽  
Lisa M. Knight ◽  
Jeanette M. Jerrell


2020 ◽  
Author(s):  
Sheryl Salis ◽  
Mini Joseph ◽  
Anuja Agarwala ◽  
Rajni Sharma ◽  
Nitin Kapoor ◽  
...  




Sign in / Sign up

Export Citation Format

Share Document